<DOC>
	<DOC>NCT00138775</DOC>
	<brief_summary>The goal of the present study is to evaluate the effect of D-serine, added to antipsychotic treatment, on negative and cognitive symptoms in schizophrenia. The investigators are hypothesizing that D-serine will improve cognitive functioning and negative symptoms.</brief_summary>
	<brief_title>Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSMIV) diagnosis of schizophrenia and\or schizoaffective disorder. Age between 18 to 64. PANSS negative symptom score higher than 19. SAS total score lower than 12. CDSS suicidal risk lower than 2 Epilepsy Meets DSMIV criteria for mental retardation. Medical condition which confounds presentation or treatment (e.g. uncontrolled diabetes mellitus, history of kidney stones, acute drug toxicity, dementia, delirium, stroke, etc.) Meets DSMIV criteria for alcohol or drug dependence in last 6 months. Meets DSMIV criteria for alcohol or drug abuse in last one month. Treatment with clozapine. Current positive pregnancy test or not using acceptable method of birth control. Meets DSMIV criteria for current anxiety or mood disorders</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>D-serine</keyword>
	<keyword>Negative symptoms</keyword>
	<keyword>Cognition</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Amino acid</keyword>
</DOC>